Karyopharm Therapeutics
Hassan Ansari is a seasoned professional in the field of clinical research and quality management with extensive experience across multiple prominent organizations. Currently serving as the Vice President of Quality at Karyopharm Therapeutics Inc., Hassan's expertise encompasses GxP, Quality Assurance, and Quality Management Systems. Prior to this, Hassan held leadership roles at AbbVie as Head of Process & Performance Excellence and at Pharmacyclics, overseeing Clinical Quality Management. A long tenure at Merck included various senior positions such as Associate Vice President and Executive Director, where responsibilities included global trial operations, clinical quality management, and process improvement. Hassan's academic qualifications include an MD PhD in Human Medicine from Ludwig-Maximilians-Universität München, a certificate in Medical Biostatistics, and a certification in Professional Coaching from the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).